Program
obudanersen sodium
Also written as “obudanersen” and “ION582”.
Its studies are mostly in Angelman Syndrome, led by Ionis Pharmaceuticals.
Furthest: phase 3, since Mar 22, 20253 company-led studies, 3 open or runningNext primary completion: Aug 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ionis Pharmaceuticals | 33 open or running | phase 3since Mar 22, 2025 | Nov 9, 2021 | Aug 2027phase 3 · NCT06914609 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2021First study: phase 2 study in Angelman SyndromeFirst studyNCT05127226 · 71 enrolled · United States, Australia, France and more
- Mar 22, 2025Phase 3 study in Angelman SyndromeNCT06914609 · 156 enrolled · United States, Australia, Canada and more
- Aug 20, 2026Phase 3 study in Angelman SyndromeNCT07782827 · 30 planned · United States
Ahead
- Aug 2027Primary completion: phase 3 study in Angelman SyndromeNCT06914609
- May 2028Primary completion: phase 3 study in Angelman SyndromeNCT07782827
- Mar 2029Primary completion: phase 2 study in Angelman SyndromeNCT05127226
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07782827Angelman Syndrome · United States | 3 | Recruiting | May 2028 | 30 |
| NCT06914609Angelman Syndrome · United States, Australia, Canada and more | 3 | Active, not recruiting | Aug 2027 | 156 |
| NCT05127226Angelman Syndrome · United States, Australia, France and more | 2 | Active, not recruiting | Mar 2029 | 71 |
How it is read
Names in the registry
- “obudanersen”, 2 entries
- “ION582”, 1 entry
Conditions, from the studies’ own filings
- Angelman Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.